Clinical Trial Update: BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs [Phase 2]

View source ↗

Summary

A Phase 2 study of BIIB057 in rheumatoid arthritis patients with inadequate response to disease-modifying antirheumatic drugs has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• BIIB057

Snippet

Sponsor: Biogen | Conditions: Rheumatoid Arthritis | Phase 2 | Status: WITHDRAWN